Browsing Tag
Ojjaara
2 posts
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.